Should the FDA speed up or slow down approval of new cancer drugs?

Should the FDA speed up or slow down approval of new cancer drugs?

By JASON SHAFRIN

CARLOS OSORIO/AP

While increased evidence requirements may improve health outcomes, it's important to consider that the delays they cause may cost lives.

READ MORE